Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
